13
views
0
recommends
+1 Recommend
2 collections
    0
    shares

          The flagship journal of the Society for Endocrinology. Learn more

      • Record: found
      • Abstract: found
      • Article: found

      The role of the p53 tumor suppressor in metabolism and diabetes

      research-article
      *,
      The Journal of endocrinology
      p53, metabolism, diabetes, insulin resistance

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In the context of tumor suppression, p53 is an undisputedly critical protein. Functioning primarily as a transcription factor, p53 helps fend off the initiation and progression of tumors by inducing cell cycle arrest, senescence or programmed cell death (apoptosis) in cells at the earliest stages of precancerous development. Compelling evidence, however, suggests that p53 is involved in other aspects of human physiology, including metabolism. Indeed, recent studies suggest that p53 plays a significant role in the development of metabolic diseases, including diabetes, and further that p53’s role in metabolism may also be consequential to tumor suppression. Here we present a review of the literature on the role of p53 in metabolism, diabetes, pancreatic function, glucose homeostasis, and insulin resistance. Additionally, we discuss the emerging role of genetic variation in the p53 pathway (single nucleotide polymorphisms) on the impact of p53 in metabolic disease and diabetes. A better understanding of the relationship between p53, metabolism and diabetes may one day better inform the existing and prospective therapeutic strategies to combat this rapidly growing epidemic.

          Related collections

          Author and article information

          Journal
          0375363
          4713
          J Endocrinol
          J. Endocrinol.
          The Journal of endocrinology
          0022-0795
          1479-6805
          13 September 2016
          09 September 2016
          November 2016
          01 November 2017
          : 231
          : 2
          : R61-R75
          Affiliations
          Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA 19104 USA
          Author notes
          Correspondence: Maureen E. Murphy, Ph.D., Program in Molecular and Cellular Oncogenesis, The Wistar Institute, 3601 Spruce St, Philadelphia PA 19104, Phone: 215-495-6870, mmurphy@ 123456wistar.org
          [*]

          Or (present address): Che-Pei Kung, Ph.D., Washington University Medical School, Division of Oncology - Campus Box 8069, 660 South Euclid Avenue, St. Louis, MO 63110, Phone: 314-747-3898, patkung@ 123456wustl.edu

          Article
          PMC5148674 PMC5148674 5148674 nihpa816292
          10.1530/JOE-16-0324
          5148674
          27613337
          9fc8f863-be45-4c56-9179-521933b778fa
          History
          Categories
          Article

          diabetes,metabolism,p53,insulin resistance
          diabetes, metabolism, p53, insulin resistance

          Comments

          Comment on this article

          Related Documents Log